Bloos F, Held J, Kluge S, Simon P, Kogelmann K, De Heer G, Kuhn SO, Jarczak D, Motsch J, Hempel G, Weiler N, Weyland A, Druener M, Gruendling M, Meybohm P, Richter D, Jaschinski U, Moerer O, Guenther U, Schaedler D, Weiss R, Putensen C, Castellanos AI, Kurzai O, Schlattmann P, Cornely OA, Bauer M, Thomas-Rueddel D (2022)
Publication Type: Journal article
Publication year: 2022
DOI: 10.1007/s00134-022-06733-x
Purpose: To investigate whether (1 -> 3)-beta-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).
APA:
Bloos, F., Held, J., Kluge, S., Simon, P., Kogelmann, K., De Heer, G.,... Thomas-Rueddel, D. (2022). (1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-022-06733-x
MLA:
Bloos, Frank, et al. "(1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial." Intensive Care Medicine (2022).
BibTeX: Download